Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: No guarantees that Baroni evaluation is complete

I understand that there is a period of two or three years after the patents expire to pursue infringement litigation. But the point is that some day the patents will no longer bring in any revenue. So what then? Does the company just close the doors? What is going to be there for investors to want to invest in this company long term? I would say looking at the potential need for secure data upgrading on the horizon, that the aquistions incorporated in PDSG, was probably the right plan. Recognizing their limitations the BOD did imo make a sound decision to pull in Baroni to help guide the direction of the product. PTSC has had a history of having a product on the cutting edge of technology that with the proper connections and marketing could have made it big but didn't ie. the Ignite chip. This time around imo the BOD has learned their lesson and are recognizing that it's not just how important the product is but being able to market the product with the right connections that can make them successful. Baroni hopefully brings this expertise to the table so the BOD can make sure they have all bases covered.

If they fail what is the reprecussions? That is a good question. Imo shareholder pressure is getting to them and they will eventually step down if they cannot deliver soon on PDSG. Its PDSG that is the measuring stick for the BOD imo and they know it. Its what they control, its thier baby. I think the patents are what they are and the control and success of that part of the business is in TPL's hands.

I just hope it all comes together for us this year.

All the best,

Steve

Share
New Message
Please login to post a reply